Skip to main content
. 2023 May 27;11(6):1033. doi: 10.3390/vaccines11061033
BLM Bleomycin
GET Gene Electrotransfer
ECT Electrochemotherapy
OS Overall survival
PFS Progression-free survival
CR Complete response
PR Partial response
SD Stable disease
PD Progressive disease
OR Objective response